🇺🇸 FDA
Patent

US 11584733

Selective histone deacetylase inhibitors for the treatment of human disease

granted A61KA61K31/45A61K31/454

Quick answer

US patent 11584733 (Selective histone deacetylase inhibitors for the treatment of human disease) held by Shuttle Pharmaceuticals, Inc. expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Shuttle Pharmaceuticals, Inc.
Grant date
Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/45, A61K31/454, A61K45/06, A61P